Knight Therapeutics - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsKnight Therapeutics

Knight Therapeutics

Knight Therapeutics Inc. is a Canadian public specialty pharmaceutical company based in Montreal, Quebec that focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. It is listed on the Toronto Stock Exchange (symbol GUD), with a market capitalization of $1.02 billion as of August 2019.

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

No data

Company Revenue

No data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Impavido	Miltefosine	2014-03-19		Cutaneous leishmaniasis , Visceral leishmaniasis , Leishmaniasis

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

,

chronic urticaria

,

,

mucocutaneous leishmaniasis

,

hiv seropositivity

,

,

cutaneous leishmaniasis

,

visceral leishmaniasis

,

drug evaluation

,

treatment adherence and compliance

Aglatimagene besadenovec

lower urinary tract symptoms

,

prostatic hyperplasia

,

,

prostatic neoplasms

,

,

neuroendocrine tumors

,

pituitary neoplasms

,

pituitary acth hypersecretion

,

pituitary diseases

,

acth-secreting pituitary adenoma

,

dumping syndrome

,

diabetes mellitus

,

,

,

hyperlipidemias

,

,

cardiovascular diseases

,

salivary gland neoplasms

,

,

,

ductal carcinoma

,

urinary bladder neoplasms

,

anxiety disorders

,

bone marrow diseases

,

,

neoadjuvant therapy

,

,

,

hypercholesterolemia

,

prostatic diseases

,

intraductal carcinoma noninfiltrating

,

small cell carcinoma

,

neuroendocrine carcinoma

,

adenocarcinoma in situ

,

radiation effects

,

,

,

hereditary breast and ovarian cancer syndrome

,

,

hypersensitivity

,

,

,

,

neoplasm metastasis

,

,

insulin resistance

,

,

,

mental disorders

,

,

,

,

lymphatic metastasis

,

sleep wake disorders

,

,

,

metabolic bone diseases

,

disease progression

,

type 2 diabetes mellitus

,

,

,

,

,

gastrointestinal diseases

,

physiological sexual dysfunction

,

positron-emission tomography

,

androgen-insensitivity syndrome

,

,

vision disorders

,

directly observed therapy

,

prostatic neoplasms

,

depressive disorder

,

major depressive disorder

,

,

castration-resistant prostatic neoplasms

,

,

metabolic syndrome

,

,

atrial fibrillation

,

prostatic hyperplasia

,

,

,

gender dysphoria

,

,

,

autonomic nervous system diseases

,

retinal diseases

,

primary dysautonomias

,

cognitive dysfunction

,

,

,

,

,

healthy volunteers/patients

,

,

breast neoplasms

,

cognitive aging

,

resistance training

,

,

,

lower urinary tract symptoms

,

renal cell carcinoma

,

urologic neoplasms

,

urogenital neoplasms

,

erectile dysfunction

,

,

severe acute respiratory syndrome-related coronavirus

,

severe acute respiratory syndrome

,

,

paraphilic disorders

,

esophageal neoplasms

,

,

magnetic resonance imaging

,

vulvar neoplasms

,

sedentary behavior

,

,

exercise therapy

,

,

chronic periodontitis

,

,

bone resorption

,

autistic disorder

,

autism spectrum disorder

,

pervasive child development disorders

,

drug-related side effects and adverse reactions

,

,

type 1 diabetes mellitus

,

,

heart disease risk factors

,

,

,

cystic fibrosis

,

positron emission tomography computed tomography

,

non-small-cell lung carcinoma

,

tendon injuries

© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use